StockData
Soligenix, Inc. logo

Soligenix, Inc. (SNGX) stock

SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$0.28−0.01 (-2.67%)

Close on Nov 17, 2026Market cap $6.11MP/E –Yield –

Soligenix ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Soligenix's ebitda for the twelve months ending Mar 31, 2022 was -$15.02M. For fiscal 2021 it was -$13.06M. The highest annual figure on record is -$2.73M in fiscal 2011.

Annual ebitda

PeriodPeriod endValueChange
FY2021Dec 31, 2021-$13.06M–
FY2020Dec 31, 2020-$18.52M–
FY2019Dec 31, 2019-$10.49M–
FY2018Dec 31, 2018-$9.01M–
FY2017Dec 31, 2017-$7.53M–
FY2016Dec 31, 2016-$5.62M–
FY2015Dec 31, 2015-$6.86M–
FY2014Dec 31, 2014-$10.52M–
FY2013Dec 31, 2013-$6.93M–
FY2012Dec 31, 2012-$4.46M–
FY2011Dec 31, 2011-$2.73M–
FY2010Dec 31, 2010-$7.69M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2022Mar 31, 2022-$4.18M–
Q4 FY2021Dec 31, 2021-$4.50M–
Q3 FY2021Sep 30, 2021-$3.36M–
Q2 FY2021Jun 30, 2021-$2.98M–
Q1 FY2021Mar 31, 2021-$2.22M–
Q4 FY2020Dec 31, 2020-$5.48M–
Q3 FY2020Sep 30, 2020-$1.80M–
Q2 FY2020Jun 30, 2020-$2.80M–
Q1 FY2020Mar 31, 2020-$8.46M–
Q1 FY2019Mar 31, 2019-$2.29M–
Q4 FY2018Dec 31, 2018-$3.15M–
Q3 FY2018Sep 30, 2018-$1.91M–
Q2 FY2018Jun 30, 2018-$1.58M–
Q1 FY2018Mar 31, 2018-$2.38M–
Q4 FY2017Dec 31, 2017-$2.56M–
Q3 FY2017Sep 30, 2017-$951.65K–
Q2 FY2017Jun 30, 2017-$2.30M–
Q1 FY2017Mar 31, 2017-$1.72M–
Q4 FY2016Dec 31, 2016-$1.27M–
Q3 FY2016Sep 30, 2016-$1.48M–
Q2 FY2016Jun 30, 2016-$987.13K–
Q1 FY2016Mar 31, 2016-$1.88M–

More Soligenix figures

See a number that looks wrong?